FDA Proposes Addition of New Inhaler to List of Essential Uses for Chlorofluorocarbon Propellants

Summary

The Food and Drug Administration (FDA) is proposing to grant a petition from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) to add a new inhaler containing metered-dose albuterol sulfate and ipratropium bromide to the list of products exempt from the ban on chlorofluorocarbon (CFC) propellants, allowing it to be used for an essential medical purpose.